bupropion has been researched along with clozapine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.17) | 18.7374 |
| 1990's | 3 (12.50) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 13 (54.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Gelenberg, AJ | 1 |
| Greenblatt, DJ; Shader, RI | 1 |
| Dahms, JL; Seiden, LS; Shaughnessy, RA | 1 |
| Evins, AE; Tisdale, T | 1 |
| Chen, L; Yang, CR | 1 |
| Green, AI; Noordsy, DL | 1 |
| Bellucci, D; Cursi-Vogel, N; Elangovan, N; Hughley, J; Stern, RG | 1 |
| Lipina, T; Roder, J | 1 |
| Canevini, MP; Castelnovo, A; Cavallotti, S; D'Agostino, A; Scarone, S; Zambrelli, E | 1 |
| Liang, CS; Yang, YC; Yeh, TC | 1 |
| Botner, B; Hund, M; Schmitz, A | 1 |
2 review(s) available for bupropion and clozapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacotherapy for schizophrenia and co-occurring substance use disorders.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Clozapine; Humans; Schizophrenia; Smoking Cessation; Substance-Related Disorders; Treatment Outcome | 2003 |
22 other study(ies) available for bupropion and clozapine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Imperfect drugs in an imperfect world.
Topics: Bulimia; Bupropion; Clinical Trials as Topic; Clozapine; Depressive Disorder; Humans; Nomifensine; Product Surveillance, Postmarketing; Schizophrenia | 1992 |
Newly marketed medications: ABCs and mind your Qs.
Topics: Anti-Anxiety Agents; Antidepressive Agents; Benzodiazepines; Bupropion; Clomipramine; Clozapine; Humans; Propiophenones | 1990 |
Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.
Topics: Animals; Antidepressive Agents; Bupropion; Clozapine; Drug Evaluation, Preclinical; Electroshock; Fluoxetine; Haloperidol; Male; Propiophenones; Rats; Rats, Inbred Strains; Reinforcement Schedule; Trazodone; Zimeldine | 1985 |
Bupropion and smoking cessation.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Clozapine; Comorbidity; Delayed-Action Preparations; Drug Therapy, Combination; Humans; Male; Schizophrenia; Schizophrenic Psychology; Smoking; Smoking Cessation | 1999 |
Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex.
Topics: Action Potentials; Animals; Benzazepines; Bupropion; Clozapine; Dopamine Antagonists; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Electric Stimulation; Excitatory Postsynaptic Potentials; GABA Antagonists; Glutamic Acid; Male; Membrane Glycoproteins; Membrane Transport Modulators; Membrane Transport Proteins; Nerve Tissue Proteins; Neurons; Patch-Clamp Techniques; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 2002 |
Clozapine-induced sialorrhea alleviated by bupropion--a case report.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Clozapine; Humans; Male; Mental Disorders; Middle Aged; Sialorrhea | 2009 |
A new model of the disrupted latent inhibition in C57BL/6J mice after bupropion treatment.
Topics: Amphetamine; Animals; Bupropion; Clozapine; Conditioning, Psychological; Disease Models, Animal; Dopamine Agonists; Dopamine Uptake Inhibitors; Drug Interactions; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred C57BL; Neural Inhibition; Phosphodiesterase 4 Inhibitors; Piperazines; Rolipram; Schizophrenic Psychology | 2010 |
Occipital seizures and visual pseudohallucinations associated with the addition of bupropion to clozapine: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Clozapine; Drug Therapy, Combination; Electroencephalography; Hallucinations; Humans; Male; Occipital Lobe; Schizophrenia; Seizures | 2015 |
A case of recurrent seizures: Drug-drug interaction between low-dose clozapine and extended-release bupropion.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Clozapine; Delayed-Action Preparations; Drug Interactions; Female; Humans; Recurrence; Seizures | 2019 |
Bupropion With Clozapine: Case Reports of Seizure After Coadministration.
Topics: Antipsychotic Agents; Bupropion; Clozapine; Female; Humans; Male; Seizures; Smoking Cessation | 2021 |